Survodutide
Research Hub — Aggregated Studies
MedTech Research Group aggregates published research from peer-reviewed journals, clinical trials, and academic institutions. We do not conduct original research. All studies cited below are the work of their respective authors and institutions. Sources are linked for verification.
This product is designated FOR RESEARCH USE ONLY (RUO). These compounds have not been approved or cleared under 21 U.S.C. § 505 and have not been evaluated by the FDA for safety, efficacy, or labeling for clinical, diagnostic, or therapeutic use in humans or animals.
MedTech Research Group will only fulfill orders to qualified researchers affiliated with accredited academic institutions, licensed research facilities, or organizations with active IRB/IACUC oversight.
Purchaser Restrictions
- Purchaser must be a qualified researcher at an accredited institution or licensed research facility
- This product may not be sold or redistributed to individual consumers, wellness clinics, health food stores, or retail establishments
- Not intended for human or animal consumption, diagnostic use, or therapeutic application
- Institutional affiliation and research purpose will be verified prior to order fulfillment
Distribution is limited to qualified research use in compliance with applicable federal and state law. These products bear the "For Research Use Only" designation per FDA labeling requirements (minimum 10 pt. font). Ref: 21 U.S.C. § 505; FD&C Act § 201(p) (unapproved new drug definition).
| Risk Tier | ORANGE |
| Category | Metabolic / Weight Management |
| Subcategory | Dual-Action Glycemic and Hepatic Regulation |
| Pharmacological Class | Dual Peptide Hormone Analog |
| Subclass | GLP-1 / Glucagon Dual Receptor Agonist |
| Molecular Type | Modified Peptide (dual-agonist, oxyntomodulin-based) |
| Origin | Synthetic analog inspired by endogenous oxyntomodulin, which naturally activates both GLP-1 and glucagon receptors |
| Regulatory Status | Investigational. Phase 3 trials by Boehringer Ingelheim for MASH (metabolic dysfunction-associated steatohepatitis) and obesity. Not FDA-approved. |
| Route of Administration | Subcutaneous injection |
| Reconstitution | Lyophilized powder; reconstitute with bacteriostatic water |
| Storage | Refrigerate (2-8°C) |
Chemical Properties
| Molecular Formula | C192H289N47O61 |
| Molecular Weight | 4232 g/mol |
| Exact Mass | 4231.1024139 Da |
| InChI Key | MEDXQFAHWBMVIM-PCLHIQTFSA-N |
| Synonyms |
|
| PubChem | View full record |
Source: NCBI PubChem — public domain data
2D structure diagram from NCBI PubChem. This is the actual molecular structure of Survodutide.
Description
Survodutide (BI 456906) is a dual GLP-1 and glucagon receptor agonist developed by Boehringer Ingelheim in collaboration with Zealand Pharma. Unlike tirzepatide (which targets GLP-1 and GIP receptors), survodutide activates GLP-1 and glucagon receptors simultaneously. This is a pharmacologically distinct approach based on the biology of oxyntomodulin, a naturally occurring gut hormone released from intestinal L-cells after meals that activates both receptor types at moderate potency.
The GLP-1 receptor agonism component provides the expected benefits: appetite suppression, improved insulin secretion, and glycemic control. The glucagon receptor agonism component — which might seem counterintuitive given that glucagon raises blood sugar — provides powerful metabolic effects including increased hepatic fat oxidation, elevated energy expenditure (thermogenesis), reduced hepatic lipogenesis, and mobilization of glycogen stores. In carefully titrated doses where the GLP-1 component offsets the hyperglycemic effect of glucagon agonism, the net result is significant weight loss AND liver fat reduction. Phase 2 trials demonstrated up to 19% weight loss at 46 weeks and — critically — up to 87% relative reduction in liver fat content, which has positioned survodutide as a leading candidate for MASH (formerly NASH) treatment.
Clinical Context
MASH/NASH is a growing epidemic with limited approved therapies. The liver fat reduction observed with survodutide far exceeds what has been seen with GLP-1 agonists alone. Boehringer Ingelheim is running Phase 3 trials for both MASH and obesity indications. If approved, survodutide would occupy a unique niche as a metabolic agent that addresses both obesity and fatty liver disease simultaneously.
- Glucagon receptor agonism may transiently increase blood glucose; careful titration is essential
- GI side effects (nausea, vomiting, diarrhea) are common and dose-dependent
- Liver enzyme elevations (ALT/AST) have been observed and require monitoring
- Contraindications likely similar to other GLP-1 agonists (MTC history, MEN 2, pancreatitis history)
- No established dosing protocol for compounded versions; clinical trial doses ranged from 0.3mg to 6.0mg weekly with slow titration
Published Research
Published Research & Clinical Data
Peer-reviewed studies and clinical trial data related to Survodutide
All research below is conducted by independent institutions. MedTech Research Group provides these references for informational purposes only.
Research citations are being compiled for this compound.
Check back soon — our team is curating peer-reviewed sources.
18 Registered Clinical Trials
Research data sourced from ClinicalTrials.gov. Public domain (U.S. National Library of Medicine).
MedTech Research Group provides these references for informational purposes. We do not conduct original research. All studies are the work of their respective authors and institutions.
18
Total Trials
4
Recruiting
4
Active
9
Completed
Sponsor: Boehringer Ingelheim · Completed: 2025-06-10
Sponsor: Boehringer Ingelheim · Completed: 2026-01-05
Sponsor: Boehringer Ingelheim · Completed: 2025-10-28
Sponsor: Boehringer Ingelheim · Completed: 2025-12-03
Sponsor: Boehringer Ingelheim · Completed: 2031-12-27
Research Library — 562 Papers
Research data sourced from OpenAlex. CC0 public domain. Articles are the work of their respective authors.
MedTech Research Group provides these references for informational purposes. We do not conduct original research. All studies are the work of their respective authors and institutions.
Type 2 diabetes mellitus in adults: pathogenesis, prevention and therapy
Xi Lu, Qingxing Xie, Xiaohui Pan, et al. · Signal Transduction and Targeted Therapy
Research by Xi Lu et al., published in Signal Transduction and Targeted Therapy. Not conducted by MedTech Research Group.
A Phase 2 Randomized Trial of Survodutide in MASH and Fibrosis
Arun J. Sanyal, Pierre Bédossa, Mandy Fraessdorf, et al. · New England Journal of Medicine
Research by Arun J. Sanyal et al., published in New England Journal of Medicine. Not conducted by MedTech Research Group.
Efficacy and Safety of GLP-1 Medicines for Type 2 Diabetes and Obesity
Daniel J. Drucker · Diabetes Care
Research by Daniel J. Drucker, published in Diabetes Care. Not conducted by MedTech Research Group.
What is the pipeline for future medications for obesity?
Eka Melson, Uzma Ashraf, Dimitris Papamargaritis, et al. · International Journal of Obesity
Research by Eka Melson et al., published in International Journal of Obesity. Not conducted by MedTech Research Group.
Metabolic dysfunction-associated steatotic liver disease: heterogeneous pathomechanisms and effectiveness of metabolism-based treatment
Norbert Stefan, Hannele Yki‐Järvinen, Brent A. Neuschwander‐Tetri · The Lancet Diabetes & Endocrinology
Research by Norbert Stefan et al., published in The Lancet Diabetes & Endocrinology. Not conducted by MedTech Research Group.
Diabetes mellitus—Progress and opportunities in the evolving epidemic
E. Dale Abel, Anna L. Gloyn, Carmella Evans‐Molina, et al. · Cell
Research by E. Dale Abel et al., published in Cell. Not conducted by MedTech Research Group.
Glucagon and GLP-1 receptor dual agonist survodutide for obesity: a randomised, double-blind, placebo-controlled, dose-finding phase 2 trial
Carel W. le Roux, Oren Steen, Kathryn Jean Lucas, et al. · The Lancet Diabetes & Endocrinology
Research by Carel W. le Roux et al., published in The Lancet Diabetes & Endocrinology. Not conducted by MedTech Research Group.
4. Comprehensive Medical Evaluation and Assessment of Comorbidities: Standards of Care in Diabetes—2025
Nuha A. ElSayed, Rozalina G. McCoy, Grazia Aleppo, et al. · Diabetes Care
Research by Nuha A. ElSayed et al., published in Diabetes Care. Not conducted by MedTech Research Group.
Incretins (GLP-1 receptor agonists and dual/triple agonists) and the liver
Philip N. Newsome, Phil Ambery · Journal of Hepatology
Research by Philip N. Newsome et al., published in Journal of Hepatology. Not conducted by MedTech Research Group.
Metabolic Dysfunction–Associated Steatotic Liver Disease (MASLD) in People With Diabetes: The Need for Screening and Early Intervention. A Consensus Report of the American Diabetes Association
Kenneth Cusi, Manal F. Abdelmalek, Caroline M. Apovian, et al. · Diabetes Care
Research by Kenneth Cusi et al., published in Diabetes Care. Not conducted by MedTech Research Group.